Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

MLA

Steeghs, N.(Neeltje), et al. Pharmacogenetics of Telatinib, a VEGFR-2 and VEGFR-3 Tyrosine Kinase Inhibitor, Used in Patients with Solid Tumors. 2011. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.ocn929971193&authtype=sso&custid=ns315887.

APA

Steeghs, N. (Neeltje), Gelderblom, A. J. (Hans), Wessels, J. A. M. (Judith), Eskens, F. A. L. M. (Ferry), Bont, N. (Natasja) de, Nortier, J. W. (Johan), & Guchelaar, H. J. (Henk J. (2011). Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.

Chicago

Steeghs, N. (Neeltje), A.J. (Hans) Gelderblom, J.A.M. (Judith) Wessels, F.A.L.M. (Ferry) Eskens, N. (Natasja) de Bont, J.W. (Johan) Nortier, and H.J. (Henk Jan) Guchelaar. 2011. “Pharmacogenetics of Telatinib, a VEGFR-2 and VEGFR-3 Tyrosine Kinase Inhibitor, Used in Patients with Solid Tumors.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.ocn929971193&authtype=sso&custid=ns315887.